Approved accessible "nivolumab and relatlimab-rmbw injection"

OPDUALAG is a combination of nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody, indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. The combination is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in people aged twelve years of age and older.

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.

OPDUALAG is a prescription medicine used to treat: • adults and children 12 years of age or older with a type of skin cancer called melanoma that has spread or cannot be removed by surgery. It is not known if OPDUALAG is safe and effective when used: • in children 12 years of age or older who weigh less than 88 pounds (40 kg), or • in children younger than 12 years of age. Active ingredients: nivolumab and relatlimab Reference ID: 4955315Inactive ingredients: Water for Injection.

How can 1 go about obtaining nivolumab and relatlimab-rmbw injection?

If nivolumab and relatlimab-rmbw injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).

OPDUALAG (nivolumab and relatlimab-rmbw) injection, for intravenous use Initial U.S. Approval: 2022

Rerefences

• For OPDUALAG (nivolumab and relatlimab-rmbw)Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details 
• Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma For More Details 
• Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma For More Details